As Abbvie INC (ABBV) Market Valuation Declined, Horan Capital Advisors LLC Lowered Its Position by $3.40 Million

September 8, 2018 - By Robert Shackelford

AbbVie Inc. (NYSE:ABBV) LogoInvestors sentiment decreased to 0.7 in 2018 Q1. Its down 0.10, from 0.8 in 2017Q4. It dived, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Alpha Cubed Invests Lc reported 0.49% of its portfolio in AbbVie Inc. (NYSE:ABBV). Independent Investors reported 2.05% stake. New York-based Mutual Of America Mngmt Limited Company has invested 0.42% in AbbVie Inc. (NYSE:ABBV). Jpmorgan Chase owns 7.33M shares for 0.15% of their portfolio. Kornitzer Cap Mgmt Incorporated Ks invested 0.03% of its portfolio in AbbVie Inc. (NYSE:ABBV). 271,915 are held by Bruce. Fort Point Prtn Limited Liability Company stated it has 116,284 shares. Guinness Asset Management invested 2.41% of its portfolio in AbbVie Inc. (NYSE:ABBV). Affinity Advsr Ltd reported 0.11% of its portfolio in AbbVie Inc. (NYSE:ABBV). Pinnacle owns 104,363 shares for 1% of their portfolio. Condor Cap Mngmt has invested 1.53% in AbbVie Inc. (NYSE:ABBV). Peak6 LP owns 0.06% invested in AbbVie Inc. (NYSE:ABBV) for 137,130 shares. Fdx Advsr invested in 0.21% or 74,467 shares. Eagle Cap Management Ltd Liability holds 32,904 shares. Chatham Cap Gp, Georgia-based fund reported 76,009 shares.

Since June 15, 2018, it had 2 insider buys, and 2 selling transactions for $6.03 million activity. RAPP EDWARD J bought $99,909 worth of stock or 1,013 shares. TILTON GLENN F also bought $496,274 worth of AbbVie Inc. (NYSE:ABBV) shares. $1.75M worth of AbbVie Inc. (NYSE:ABBV) was sold by RICHMOND TIMOTHY J..

Horan Capital Advisors Llc decreased its stake in Abbvie Inc (ABBV) by 54.15% based on its latest 2018Q1 regulatory filing with the SEC. Horan Capital Advisors Llc sold 36,126 shares as the company’s stock declined 16.83% with the market. The institutional investor held 30,591 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $2.90M, down from 66,717 at the end of the previous reported quarter. Horan Capital Advisors Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $142.60 billion market cap company. The stock increased 0.46% or $0.43 during the last trading session, reaching $94.17. About 4.05 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since September 8, 2017 and is uptrending. It has outperformed by 39.84% the S&P500.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on October, 26. They expect $2.01 EPS, up 42.55 % or $0.60 from last year’s $1.41 per share. ABBV’s profit will be $3.04B for 11.71 P/E if the $2.01 EPS becomes a reality. After $2.00 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 0.50 % EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “Senate vote approaches on bill to combat opioid crisis” on September 07, 2018, also Seekingalpha.com with their article: “AbbVie: Still A Compelling Buy?” published on August 27, 2018, Seekingalpha.com published: “AbbVie: FCFs Ensure Sweet Dividends And Buybacks” on August 30, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Et Tu, Bruton?” published on August 30, 2018 as well as Seekingalpha.com‘s news article titled: “Buy United Parcel Service – Cramer’s Lightning Round (9/6/18)” with publication date: September 07, 2018.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 14 analysts covering AbbVie (NYSE:ABBV), 5 have Buy rating, 2 Sell and 7 Hold. Therefore 36% are positive. AbbVie has $15700 highest and $78 lowest target. $112.73’s average target is 19.71% above currents $94.17 stock price. AbbVie had 21 analyst reports since March 22, 2018 according to SRatingsIntel. As per Monday, March 26, the company rating was maintained by Bank of America. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Jefferies on Friday, April 13. The stock has “Buy” rating by Piper Jaffray on Tuesday, April 10. PiperJaffray downgraded the stock to “Neutral” rating in Friday, June 1 report. As per Friday, June 22, the company rating was maintained by Credit Suisse. The firm earned “Buy” rating on Monday, July 30 by Bank of America. Credit Suisse downgraded AbbVie Inc. (NYSE:ABBV) on Wednesday, May 30 to “Underperform” rating. The company was maintained on Thursday, April 5 by Barclays Capital. The firm earned “Hold” rating on Friday, June 1 by Piper Jaffray. On Friday, March 23 the stock rating was maintained by Jefferies with “Buy”.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.